Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2020 Financial Results on July 30, 2020
July 23 2020 - 8:30AM
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage
biopharmaceutical company, today announced that the Company will
host a conference call and webcast on July 30, 2020 at 4:30 pm ET
(1:30 pm PT) to provide a business update and report second quarter
2020 financial results.
The conference call can be accessed by dialing 1-855-327-6837
(toll-free domestic) or 1-631-891-4304 (international) and using
the conference ID 10010533. The live webcast may be accessed via
the investor relations section of the Corvus website. A replay of
the webcast will be available on Corvus' website for 90 days.
About Corvus Pharmaceuticals Corvus
Pharmaceuticals is a clinical-stage biopharmaceutical company.
Corvus’ lead product candidates are ciforadenant (CPI-444), a small
molecule inhibitor of the A2A receptor, and CPI-006, a humanized
monoclonal antibody directed against CD73 that exhibits
immunomodulatory activity and activation of immune cells. These
product candidates are being studied in ongoing Phase 1b/2 and
Phase 1/1b clinical trials in patients with a wide range of
advanced solid tumors. Ciforadenant is being evaluated in a
successive expansion cohort Phase 1b/2 trial examining its activity
both as a single agent and in combination with an anti-PD-L1
antibody. CPI-006 is being evaluated in a multicenter Phase 1/1b
clinical trial as a single agent, in combination with ciforadenant
and pembrolizumab. The Company’s third cancer clinical program,
CPI-818, an oral, small molecule drug that has been shown to
selectively inhibit ITK, is in a multicenter Phase 1/1b clinical
trial in patients with several types of T-cell lymphomas. The
Company is also evaluating CPI-006 as a treatment for COVID-19
patients. For more information, visit
www.corvuspharma.com.
INVESTOR CONTACT: Leiv Lea Chief
Financial Officer Corvus Pharmaceuticals, Inc.
650-900-4522LLea@corvuspharma.com
MEDIA CONTACT: Sheryl Seapy W2O pure +1
213-262-9390sseapy@purecommunications.com
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Apr 2023 to Apr 2024